CYGNOS BioTech is developing propriety antimicrobial therapeutics protected under several patents. PVX that will be commercialized for human and veterinary clinical markets. PVX is currently manufactured by chemical modification of the protein to ultimately promote biologic activity, either antiviral or antitumor (MMX).
CYGNOS PVX has already demonstrated efficacy in companion animals (dogs, cats, horses and birds).
CYGNOS has been awarded 2 FDA investigational product INADs for PVX and MMX.
In parallel, CYGNOS is seeking funding to advance product development through FDA for the approval of the Animal INADs and a Human IND submission.
Company Details
- Employees
- 4
- Founded
- -
- Address
- P.o. Box 160471, Miami,fl 33116-0471,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.cygnosbiotech.com/
- Keywords
- Sandwich.
- HQ
- Miami, FL
Cygnos Biotech Llc Questions
Cygnos Biotech Llc's website is https://www.cygnosbiotech.com/
Cygnos Biotech Llc's LinkedIn profile is https://www.linkedin.com/company/cygnosbiotech
Cygnos Biotech Llc has
4 employees.
View email and phone details for 4
employees at Cygnos Biotech Llc.
Cygnos Biotech Llc's industry is
Biotechnology Research
Cygnos Biotech Llc's top competitors are
Dynport Vaccine Company Llc, A Gdit Company,
Biowaived Ltd,
Indo Search,
Neural Cloud Solutions Inc.,
Pikralida,
Bioveric Pharmaceuticals, Inc.,
Transposon Therapeutics, Inc.,
The Confluencial,
Ixpert Advisors,
The Siesta Group.
Cygnos Biotech Llc's categories are Biotechnology Research
Cygnos Biotech Llc's founding year is 2022
